While these results should be considered preliminary due to the open-label design, the [buccal film] was overall safe and well tolerated, and it appeared to provide adequate symptom control, in the treatment of opioid-dependent subjects previously controlled on [sublingual tablet or film] for a minimum of 30 days. [...].

**TAKE HOME POINT:** 

*BIV: Improving Implementation and Outcomes of Office-Based Treatment of Opioid Dependence in the VA*

This information is supported and provided by the Substance Use Disorder Quality Enhancement Research Initiative (SUD-QUERI), Center of Excellence in Substance Abuse Treatment and Education (CESATE), the Mental Illness Research, Education and Clinical Centers (MIRECC), and the Program Evaluation and Resource Center (PERC) within the Department of Veterans Affairs. Please contact Dan Harding at John.HardingJr@va.gov or 412-360-2207 with questions or comments.